AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05165407
Drug: Sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab 200mg will be intravenously administered on Day 1 of each cycle
Trial: NCT05165407
Drug: Surufatinib
RxNorm normalized name: Surufatinib
DrugBank: Surufatinib (DB15106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surufatinib 250mg will be taken orally once daily continuously
Trial: NCT05901051
Drug: vonoprazan
RxNorm normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Potassium competitive acid blocker
Trial: NCT05901051
Drug: Amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antibiotics for H. pylori eradication
Trial: NCT06162169
Drug: JAB-21822
RxNorm normalized name: JAB-21822
DrugBank: JAB-21822 (DB17478)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JAB-21822 was administered orally
Trial: NCT06162169
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole was administered orally
Trial: NCT06162169
Drug: Omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole was administered orally
Trial: NCT06162169
Drug: Rifampicin
RxNorm normalized name: Rifampicin
DrugBank: Rifampin (DB01045)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifampicin was administered orally
Trial: NCT06578182
Drug: Colchicine
RxNorm normalized name: Colchicine
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colchicine 0.5mg tablets once a day for 3 to 4.5 years
Trial: NCT06128863
Drug: Pembrolizumab, Eftilagimod alpha
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Eftilagimod alpha 20 mg s.c. every 2 weeks (5 doses), Pembrolizumab 200 mg i.v. every 3 weeks (3 cycles), Radiotherapy 50 Gy (25 x 2 Gy)
Trial: NCT06476808
Drug: BMS-986463
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT05621811
Drug: Naronapride
RxNorm normalized name: Naronapride
DrugBank: Naronapride (DB05542)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naronapride is a 5HT-4 agonist
Trial: NCT05326776
Drug: Pitocin
RxNorm normalized name: Pitocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: At each session, 4mcg/2ml oxytocin or 2ml isotonic saline (0.9% sodium chloride; placebo control) will be injected into the middle of the dorsal forearm. Sessions will be separated by at least 48 hours to ensure drug clearance.
Trial: NCT05356351
Drug: RC48- ADC
RxNorm normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: RC48-ADC 2.0 mg/kg D1,Triplizumab 3mg/kg D2，Q2W
Trial: NCT05689047
Drug: Pyronaridine 360 mg
RxNorm normalized name: Pyronaridine
DrugBank: Pyronaridine (DB12975)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 360 mg of pyronaridine tablets in combination with M5717 under fasting condition.
Trial: NCT05689047
Drug: Pyronaridine 360 mg
RxNorm normalized name: Pyronaridine
DrugBank: Pyronaridine (DB12975)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants with weight \>=24 to \<45 kg will receive 360 mg of tablets in combination with M5717 under fasting condition.
Trial: NCT05689047
Drug: Pyronaridine 540 mg
RxNorm normalized name: Pyronaridine
DrugBank: Pyronaridine (DB12975)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants with weight \>=45 to \<65 kg will receive 540 mg of Pyronaridine tablets in combination with M5717 under fasting condition.
Trial: NCT05689047
Drug: Pyronaridine 720 mg
RxNorm normalized name: Pyronaridine
DrugBank: Pyronaridine (DB12975)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants with weight \>=65 kg will receive 720 mg of Pyronaridine tablets in combination with M5717 under fasting condition.
Trial: NCT05689047
Drug: Pyronaridine-artesunate (Pyramax) 360 mg/120 mg
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants with weight \>=24 to \<45 kg will receive dose of 360/120 mg dose of Pyronaridine- artesunate (Pyramax) tablets under fasting condition.
Trial: NCT05689047
Drug: Pyronaridine- artesunate (Pyramax) 540 mg/180 mg
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants with weight \>=45 to \<65 kg will receive 540/180 mg dose of Pyronaridine-artesunate (Pyramax) tablets under fasting condition.
Trial: NCT05689047
Drug: Pyronaridine-artesunate (Pyramax) 720 mg/240 mg
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants with weight \>=65 kg will receive 720/240 mg dose of Pyronaridine- artesunate (Pyramax) tablets under fasting condition.
Trial: NCT06036095
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhalational maintenance of anesthesia group using sevoflurane
Trial: NCT06036095
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous maintenance of anesthesia group using propofol
Trial: NCT06506565
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infusion during wound care
Trial: NCT00000820
Drug: Aldesleukin
RxNorm normalized name: Aldesleukin
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05023343
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 mL Ropivacaine 0,75% administered as a unilateral TQL block
Trial: NCT04956042
Drug: Fosciclopirox
RxNorm normalized name: Fosciclopirox
DrugBank: Fosciclopirox (DB18772)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosciclopirox, 900 mg/m2 administered as a 20-minute IV infusion once daily on D1-D5 of each 21-day treatment cycle
Trial: NCT04956042
Drug: Fosciclopirox + Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fosciclopirox - 900 mg/m2 administered as a 20-minute IV infusion once daily on D1-D5 of each 21-day treatment cycle~Cytarabine - 1g/m2 once daily on D1-D5 of each 21-day treatment cycle
Trial: NCT05701306
Drug: APG-115
RxNorm normalized name: APGA
DrugBank: Aminopterin (DB08878)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally once every other day(QOD) for 2 weeks and suspended for 1 week, 21 days as a cycle.
Trial: NCT05701306
Drug: APG-2575
RxNorm normalized name: APGA
DrugBank: Aminopterin (DB08878)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally once a day (QD) for 21 days, 21 days as a cycle.
Trial: NCT04962672
Drug: Propofol group
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 patients scheduled for the elective craniotomy for suspected high-grade gliomas resection will be enrolled and further randomized to receive total intravenous anesthesia (propofol group). Standard fasting and monitoring guidelines will be instituted. All patients will be induced and intubated after administration of intravenous boluses of fentanyl, propofol and rocuronium. For the maintenance phase of anesthesia, patients in the propofol group will receive continuous infusions of propofol and remifentanil. No patients will receive nitrous oxide. Anesthesia will be titrated to keep depth of anesthesia between 35- 55. All patients will be maintained on oxygen in air mixture (40%) and titrate the End Tidal Carbon Dioxide (ETCO2) concentration between 25-30 mm Hg.
Trial: NCT04962672
Drug: Sevoflurane group
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 patients scheduled for the elective craniotomy for suspected high-grade gliomas resection will be enrolled and further randomized to receive Volatile (sevoflurane group) agent for the maintenance phase of anesthesia. Standard fasting and monitoring guidelines will be instituted. All patients will be induced and intubated after administration of intravenous boluses of fentanyl, propofol and rocuronium. For the maintenance phase of anesthesia, patients in the volatile inhalational anesthesia group received a volatile inhalational agent (sevoflurane) and remifentanil infusion. No patients will receive nitrous oxide. Anesthesia will be titrated to keep depth of anesthesia between 35- 55. All patients will be maintained on oxygen in air mixture (40%) and titrate the End Tidal Carbon Dioxide (ETCO2) concentration between 25-30 mm Hg.
Trial: NCT04859283
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal dexmedetomidine 1µg/kg will be administered 30min before the induction of anesthesia using a LMA MAD Nasal-device
Trial: NCT06700499
Drug: AK120 300mg Q2W (JAK inhibitor users need to double the initial dose)
RxNorm normalized name: Antisense Oligonucleotide Inhibitor Of The Expression Of Superoxide Dismutase 1 Gene
DrugBank: Tofersen (DB14782)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AK120 300mg Q2W SC until week 14(JAK inhibitor users need to receive a first dose of 600mg SC)
Trial: NCT05689034
Drug: Azvudine
RxNorm normalized name: Azvudine
DrugBank: Azvudine (DB16407)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azvudine po. 5mg daily for 7 days
Trial: NCT06361537
Drug: OCTA-C1-INH
RxNorm normalized name: C1-INH
DrugBank: Human C1-esterase inhibitor (DB06404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OCTA-C1-INH is a stable, sterile, virus-inactivated, nano-filtered, highly purified concentrate of human C1-INH prepared from pooled human plasma. After reconstitution in 2.5mL water for injection, the solution can be administered as a slow IV injection. OCTA-C1-INH is given as a dose of 20 IU/kg body weight (BW)
Trial: NCT05385744
Drug: Teriflunomide
RxNorm normalized name: Teriflunomide
DrugBank: Teriflunomide (DB08880)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Teriflunomide 14 mg
Trial: NCT05135312
Drug: Etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: TNF-alpha inhibitors improve nail psoriasis.
Trial: NCT06568185
Drug: Alpha-Lipoic Acid/Vitamin/Mineral Supplement PolyMVA
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIONERV® s the first combination of alpha lipoic acid 300mg and vitamin B complex. Bionerv® is in oral film-coated, orange colour, oblong shape and no marking and embossing on the tablet. Each tablet contains 4 active ingredients as follows: Alpha lipoic acid 300mg, Vitamin B12 (methylcobalamin) 500mcg, Vitamin B6 (pyridoxine) 8mg, Vitamin B1 (thiamine) 39mg. To be taken after meal 1 tablet once daily.
Trial: NCT06108596
Drug: Sintilimab with Interleukin-2+CAPOX
RxNorm normalized name: Interleukin-2 aldesleukin
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab with Interleukin-2+CAPOX
Trial: NCT06476834
Drug: Deucravacitinib
RxNorm normalized name: Deucravacitinib
DrugBank: Deucravacitinib (DB16650)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT06553872
Drug: Pirtobrutinib
RxNorm normalized name: Pirtobrutinib
DrugBank: Pirtobrutinib (DB17472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirtobrutinib is a non-covalent BTKi that has preserved activity in the presence of mutations that drive BTKi resistance.
Trial: NCT06553872
Drug: Brexucabtagene Autoleucel
RxNorm normalized name: Brexucabtagene autoleucel
DrugBank: Brexucabtagene autoleucel (DB15699)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brexucabtagene autoleucel is an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy (brexu-cel).
Trial: NCT04682587
Drug: Axitinib
RxNorm normalized name: Axitinib
DrugBank: Axitinib (DB06626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inlyta, axitinib
Trial: NCT04682587
Drug: Avelumab
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avelumab, Bavencio
Trial: NCT04682587
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab, Keytruda
Trial: NCT05534802
Drug: Ulinastatin
RxNorm normalized name: ulinastatin
DrugBank: Ulinastatin (DB12038)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On the basis of conventional treatment, according to the instructions or previous research doses (general anesthesia and tracheal intubation, after cardiopulmonary bypass transfer starts): 10,000 U/kg Ulinastatin (National Medicine Approval No. H19990134, Guangdong Tianpu Biochemical Pharmaceutical Co., Ltd. Co., Ltd., Guangzhou, China) was dissolved in 50 ml of normal saline for 1 hour and pumped through the central vein.
Trial: NCT05137054
Drug: Linvoseltamab
RxNorm normalized name: Linvoseltamab
DrugBank: Linvoseltamab (DB17447)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linvoseltamab is administered by intravenous (IV) infusion
Trial: NCT05137054
Drug: Daratumumab
RxNorm normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Daratumumab is administered by IV infusion and/or subcutaneous (SC) injection; SC injection may be used after a minimum of 2 cycles of IV administration at the investigator's discretion.
Trial: NCT05137054
Drug: Carfilzomib
RxNorm normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carfilzomib is administered by IV infusion
Trial: NCT05137054
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide is administered by mouth (PO) as a capsule
Trial: NCT05137054
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib is administered by IV infusion or SC injection
Trial: NCT05137054
Drug: Pomalidomide
RxNorm normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pomalidomide is administered by mouth (PO) as a capsule
Trial: NCT05137054
Drug: Isatuximab
RxNorm normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Isatuximab is administered by IV infusion
Trial: NCT05137054
Drug: Fianlimab
RxNorm normalized name: Fianlimab
DrugBank: Fianlimab (DB18858)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fianlimab is administered by IV infusion
Trial: NCT05137054
Drug: Cemiplimab
RxNorm normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cemiplimab is administered by IV infusion
Trial: NCT05137054
Drug: Nirogacestat
RxNorm normalized name: NIROGACESTAT
DrugBank: Nirogacestat (DB12005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nirogacestat is administered by mouth (PO) as a tablet
Trial: NCT05191706
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: single anterior chamber injection
Trial: NCT05666076
Drug: Bupivacaine and prilocaine hydrochloride
RxNorm normalized name: Prilocaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The investigators will perform a pericapsular nerve block on that patient group for postoperative analgesia with bupivacaine and prilocaine hydrochloride
Trial: NCT05666076
Drug: Bupivacaine and prilocaine hydrochloride
RxNorm normalized name: Prilocaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The investigators will perform a suprascapular nerve block on that patient group for postoperative analgesia with bupivacaine and prilocaine hydrochloride
Trial: NCT05984511
Drug: Atezolizumab plus Bevacizumab
RxNorm normalized name: Atezolizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Atezolizumab/bevacizumab (1,200 mg atezolizumab plus 15 mg/kg bevacizumab intravenously every 3 weeks) .
Trial: NCT04084678
Drug: Ralinepag
RxNorm normalized name: Ralinepag
DrugBank: Ralinepag (DB12462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ralinepag
Trial: NCT06181227
Drug: AVD-104
RxNorm normalized name: Avdoralimab
DrugBank: Avdoralimab (DB16392)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An intravitreal injection of 50 microliters at the doses described will be given. Visual acuity, optical coherence tomography thickness and vascular perfusion will be evaluated for an effect of the drug.
Trial: NCT05886816
Drug: Mitoquinone/mitoquinol mesylate
DrugBank: Mitoquinone (DB05063)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitochondrial antioxidant
Trial: NCT04909931
Drug: Vitamin D 2
RxNorm normalized name: VITAMIN D 25000UNT CAP
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized allocation first arm : add on vitamin D supplementation 40,000 iu/week for 12 weeks
Trial: NCT06107738
Drug: Iberdomide
RxNorm normalized name: Iberdomide
DrugBank: Iberdomide (DB12101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iberdomide 1.0mg daily for days 1-21 of a 28-day cycle, an increase to 1.3 mg daily on Day 1-21 of a 28-day cycle is allowed at cycle 4 or higher if the 1.0 mg dose was well tolerated.
Trial: NCT06107738
Drug: Daratumumab/rHuPH20 Co-formulation
DrugBank: Daratumumab (DB09331)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Daratumumab/rHuPH20 will be dosed as follows:~* Daratumumab/rHuPH20 1800 mg SC days 1, 8, 15, 22 (28-day cycle; cycles 1-2)~* Daratumumab/rHuPH20 1800 mg SC days 1, 15 (28-day cycle; cycles 3-6)~* Daratumumab/rHuPH20 1800 mg SC day 1 (28-day cycle; cycles 7-26)
Trial: NCT05597306
Drug: Bomedemstat
RxNorm normalized name: Bomedemstat
DrugBank: Bomedemstat (DB17234)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bomedemstat will be administered orally once daily via capsule.
Trial: NCT05597306
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Venetoclax will be administered orally once daily via tablet.
Trial: NCT06152575
Drug: Elranatamab
RxNorm normalized name: ELRANATAMAB
DrugBank: Elranatamab (DB15395)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elranatamab will be administered subcutaneously
Trial: NCT06152575
Drug: Elotuzumab
RxNorm normalized name: elotuzumab
DrugBank: Elotuzumab (DB06317)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Elotuzumab will be administered intravenously
Trial: NCT06152575
Drug: Pomalidomide
RxNorm normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pomalidomide will be administered orally
Trial: NCT06152575
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone will be administered orally
Trial: NCT06152575
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib will be administered subcutaneously or intravenously
Trial: NCT06152575
Drug: Carfilzomib
RxNorm normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carfilzomib will be administered intravenously
Trial: NCT05882734
Drug: M1774
RxNorm normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In Phase 1b, M1774 will be administered as dosing regimen 1 or dosing regimen 2 until disease progression, death discontinuation criteria or any other reason. The selected dosing regimen of M1774 will be administered in all arms of Phase 2a.
Trial: NCT05882734
Drug: Cemiplimab
RxNorm normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cemiplimab will be administered as an intravenous infusion every 3 weeks in all arms of Phase 1b and Phase 2a until disease progression, death discontinuation criteria or any other reason.
Trial: NCT06254521
Drug: Tislelizumab combined with chemotherapy
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Oxaliplatin Oxaliplatin 130mg/m2 for chemotherapy on Day 1 every 3 weeks and repeat for 2 or 4 cycles. The dose reduction protocol for oxaliplatin-induced toxicity was implemented according to the report in BJC (2018) 118:1322-1328.~Drug: Capecitabine Oral Capecitabine 1000 mg/m2 twice daily combined with oxaliplatin chemotherapy from Day 1 to Day 14 every 3 weeks and repeat for 2 or 4 cycles. The dose reduction protocol for capecitabine-induced toxicity was implemented according to the report in BJC (2018) 118:1322-1328.~Drug: Anti-PD-1 Monoclonal Antibody 200 mg on Day 1 every 3 weeks and repeat for 2 or 4 cycles. The incidence of adverse events with Anti-PD-1 Monoclonal Antibodies is relatively low. The PD-1 monoclonal antibody (Tislelizumab) dose adjustment was implemented according to the prescribing information.~Other Names:~Tislelizumab~Procedure: Colectomy The specific surgical approach, whether it be laparoscopic
Trial: NCT06065540
Drug: Cagrilintide
RxNorm normalized name: Cagrilintide
DrugBank: Cagrilintide (DB18887)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive once-weekly s.c injection of cagrilintide at escalating doses every week until maintenance dose 1 and dose 2 of cagrilintide is reached.
Trial: NCT06065540
Drug: Semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive once-weekly s.c injection of semaglutide at escalating doses every week until maintenance dose 1 and dose 2 of semaglutide is reached.
Trial: NCT06065540
Drug: Placebo cagrilintide
DrugBank: Cagrilintide (DB18887)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo matched to cagrilintide subcutaneously.